Table 2.
Risk of Clinical Outcomes According to Reclassification of the eGFR with the Measurement of Cystatin C, as Compared with Creatinine, in the 11 General-Population Cohorts.*
| Outcome and Category of Creatinine- Based eGFR (ml/min/1.73 m2) |
Total No. of Participants Evaluated |
Reclassification to Higher eGFR | No Reclassification | Reclassification to Lower eGFR | |||
|---|---|---|---|---|---|---|---|
| %of Participants |
Adjusted Hazard Ratio (95% CI) |
%of Participants |
Adjusted Hazard Ratio (95% CI) |
%of Participants |
Adjusted Hazard Ratio (95% CI) |
||
| Death from any cause | 1260 events |
6110 events |
4981 events |
||||
| ≥90 | 38,287 | NA | NA | 70 | Reference | 30 | 1.36 (1.24–1.48) |
| 60–89 | 43,630 | 32 | 0.88 (0.76–1.01) | 55 | Reference | 14 | 1.57 (1.39–1.78) |
| 45–59 | 6,358 | 42 | 0.66 (0.57–0.77) | 34 | Reference | 24 | 1.67 (1.49–1.88) |
| 30–44 | 1,917 | 38 | 0.77 (0.61–0.98) | 44 | Reference | 19 | 1.72 (1.24–2.37) |
| 15–29 | 427 | 24 | 0.60 (0.27–1.36) | 65 | Reference | 11 | 3.04 (1.87–4.95) |
| 0–14 | 131 | 20 | 0.44 (0.14–1.36) | 80 | Reference | NA | NA |
| Death from cardiovascular causes | 340 events |
1572 events |
1281 events |
||||
| ≥90 | 25,691 | NA | NA | 71 | Reference | 29 | 1.37(1.09–1.71) |
| 60–89 | 32,283 | 33 | 0.94 (0.70–1.28) | 54 | Reference | 13 | 1.44(1.19–1.74) |
| 45–59 | 4,458 | 47 | 0.79 (0.61–1.04) | 33 | Reference | 21 | 1.60 (1.30–1.95) |
| 30–44 | 1,276 | 43 | 0.66 (0.42–1.02) | 39 | Reference | 18 | 1.19(0.77–1.83) |
| 15–29 | 231 | 23 | 0.15 (0.03–0.74) | 66 | Reference | 12 | 2.83 (0.79–10.18) |
| 0–14 | 71 | 17 | ND | 83 | Reference | NA | NA |
| End-stage renal disease | 52 events |
198 events |
107 events |
||||
| ≥90 | 16,898 | NA | NA | 68 | Reference | 32 | 3.37(0.93–12.15) |
| 60–89 | 17,453 | 29 | 0.71 (0.34–1.48) | 58 | Reference | 13 | 2.66 (1.52–4.67) |
| 45–59 | 2,468 | 35 | 0.20 (0.08–0.53) | 37 | Reference | 27 | 1.72 (0.91–3.27) |
| 30–44 | 758 | 28 | 0.39 (0.16–0.90) | 53 | Reference | 20 | 2.04 (1.14–3.65) |
| 15–29 | 220 | 26 | 7.15 (0.04–1257)† | 64 | Reference | 10 | 2.23 (0.74–6.78) |
| 0–14 | 75 | 20 | 2.39 (0.72–7.87) | 80 | Reference | NA | NA |
Reclassification of the eGFR to a higher value with the measurement of cystatin C was associated with a decreased risk of a study outcome. Conversely, reclassification of the eGFR to a lower value was associated with an increased risk. Hazard ratios were adjusted for age, sex, race, smoking status, systolic blood pressure, total cholesterol level, presence or absence of diabetes, presence or absence of a history of cardiovascular disease, body-mass index, and the level of albuminuria. NA denotes not applicable, and ND not done because of small sample size.
The 95% confidence interval is very wide in this category.